Real-World Study Reveals GLP-1 Patients Frequently Transition to Alternative Therapies Following Medication Discontinuation

New research shows patients stopping GLP-1 drugs frequently resume treatment or try alternatives, explaining why weight regain is lower than expected.

By: AXL Media

Published: Mar 17, 2026, 4:15 AM EDT

Source: Information for this report was sourced from News-Medical

Shifting Patterns in Obesity Pharmacotherapy

The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 receptor agonists has fundamentally altered the management of obesity and type 2 diabetes mellitus. According to recent clinical data, the initial popularity of these medications, driven by significant cardiovascular and metabolic benefits, is now being met with complex long-term usage patterns. A retrospective study focusing on thousands of patients found that those who discontinue these injectable therapies often do not abandon treatment entirely. Instead, a substantial percentage of individuals re-enter the therapeutic fold within a year, either by resuming their initial medication or exploring a variety of pharmaceutical and lifestyle-based alternatives to maintain their health gains.

Resumption Rates and Insurance Disparities

Data from healthcare systems in Ohio and Florida show that approximately 19.6 percent of patients who discontinued their medication eventually restarted the original drug. However, the study highlighted a notable disparity between patients treated for diabetes and those treated specifically for obesity. Individuals with type 2 diabetes were significantly more likely to restart their prescriptions compared to those using the drugs solely for weight management, a trend the researchers attribute to broader insurance coverage for diabetic indications. For many patients, the decision to stop or restart therapy is heavily influenced by external economic factors, including pricing structures and the availability of lower-cost doses through non-traditional channels.

Transitioning to Alternative Medical Interventions

Beyond those who returned to their initial prescriptions, roughly 35 percent of the study participants adopted different weight-management strategies. According to the research, approximately 27.4 percent of patients switched to alternative medications such as phentermine, topiramate, or bupropion, while others transitioned between the two leading GLP-1 options, semaglutide and tirzepatide. This high rate of switching suggests that the discontinuation of a specific drug does not necessarily indicate a failure of the patient’s weight-loss journey, but rather a pivot to more sustainable or accessible forms of treatment. Smaller percentages of patients sought specialized healthcare visi...